A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer

Sung Joon Hong, Kang Su Cho, Han Yong Choi, Hanjong Ahn, Choung Soo Kim, Byungha Chung

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. Patients and Methods: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4 mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). Results: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. Conclusion. Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.

Original languageEnglish
Pages (from-to)1001-1008
Number of pages8
JournalYonsei Medical Journal
Volume48
Issue number6
DOIs
Publication statusPublished - 2007 Dec 1

Fingerprint

zoledronic acid
Prostatic Neoplasms
Hormones
Neoplasm Metastasis
Safety
Pain
Analgesics
Creatinine
Quality of Life
Bone and Bones
Equipment and Supplies
Bone Neoplasms
Controlled Clinical Trials
Serum

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Hong, Sung Joon ; Cho, Kang Su ; Choi, Han Yong ; Ahn, Hanjong ; Kim, Choung Soo ; Chung, Byungha. / A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. In: Yonsei Medical Journal. 2007 ; Vol. 48, No. 6. pp. 1001-1008.
@article{8219538d142942fcb8fa2f043ac651be,
title = "A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer",
abstract = "The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. Patients and Methods: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4 mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). Results: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. Conclusion. Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.",
author = "Hong, {Sung Joon} and Cho, {Kang Su} and Choi, {Han Yong} and Hanjong Ahn and Kim, {Choung Soo} and Byungha Chung",
year = "2007",
month = "12",
day = "1",
doi = "10.3349/ymj.2007.48.6.1001",
language = "English",
volume = "48",
pages = "1001--1008",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "6",

}

A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. / Hong, Sung Joon; Cho, Kang Su; Choi, Han Yong; Ahn, Hanjong; Kim, Choung Soo; Chung, Byungha.

In: Yonsei Medical Journal, Vol. 48, No. 6, 01.12.2007, p. 1001-1008.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer

AU - Hong, Sung Joon

AU - Cho, Kang Su

AU - Choi, Han Yong

AU - Ahn, Hanjong

AU - Kim, Choung Soo

AU - Chung, Byungha

PY - 2007/12/1

Y1 - 2007/12/1

N2 - The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. Patients and Methods: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4 mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). Results: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. Conclusion. Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.

AB - The short-term safety and efficacy of zoledronic acid for the treatment of skeletal metastasis was evaluated in patients with hormone-refractory prostate cancer. Patients and Methods: A total of 19 hormone-refractory prostate cancer patients with bone metastases were enrolled. All patients received up to six infusions of zoledronic acid (4 mg, given intravenously over 15 minutes, every 3-4 weeks). Safety was assessed by monitoring a dverse events and serum creatinine levels. Efficacy was assessed by monitoring skeletal-related events, brief pain inventory score, quality of life score, type of pain medication, and analgesic score. Mean age of patients was 67.3 years (46-86 years), mean time from diagnosis of bone metastases was 27.6 months (0-117 months), and mean time from diagnosis of hormone-refractory disease was 7.5 months (0-26 months). Results: There was no clinically significant change in serum creatinine levels. Eleven adverse events (musculoskeletal disorders and systemic disorders) in 8 patients were classed as having a possible relationship to study drug. Fifteen patients completed six courses of zoledronic acid infusion. There were no significant changes in the brief pain inventory composite scores, quality of life questionnaire scores or analgesic score. No new skeletal-related events developed during the treatment period. Conclusion. Zoledronic acid administered in this study as a 15-minute infusion demonstrated an acceptable and well-known safety profile in patients with refractory prostate cancer with bone metastases. However, prospective placebo- controlled clinical trials are required to elucidate the efficacy of zoledronic acid.

UR - http://www.scopus.com/inward/record.url?scp=38349028914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38349028914&partnerID=8YFLogxK

U2 - 10.3349/ymj.2007.48.6.1001

DO - 10.3349/ymj.2007.48.6.1001

M3 - Article

VL - 48

SP - 1001

EP - 1008

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 6

ER -